Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年5月2日
	新闻
	Lung Cancer's Hidden Cellular Origins Unraveled | Inside Precision Medicine Inside Precision Medicine When exposed to cancer-causing substances, basal cells undergo cellular changes that prepare them for early lesions and lung squamous cell ... 标记为不相关
	Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC - OncLive OncLive ... Lung Cancer Screening Program at Memorial Sloan Kettering Cancer Center in New York. Related Content. Oncology Experts Discuss the Long-Term ... 标记为不相关
	Higher AFM24 Exposure Boosts Response in Advanced NSCLC: AACR Data Targeted Oncology Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery · Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care. 标记为不相关
	Dose Escalation of Fluorodeoxyglucose PET Guided Radiotherapy for Locally Advanced NSCLC The ASCO Post ... Oncology article. Disclosure: The study was supported by the Danish Research Center for Lung Cancer. For full disclosures of the study authors ... 标记为不相关
	Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With ... ASCO Publications ... cancer. When these genes are expressed, they indicate a worse prognosis for patients with lung cancer, prostate cancer and colon cancer. Future ... 标记为不相关
	50,000 lung cancer patients treated late in past 10 years – and it's getting worse - MSN MSN Almost 50,000 lung cancer patients have not been seen on time over the last 10 years, with thousands currently waiting more than three months to ... 标记为不相关
	Exploring ribosome biogenesis in lung adenocarcinoma to advance prognostic methods ... Journal of Translational Medicine - BioMed Central Lung cancer (LC), characterized by its high mortality rate, is a prevalent malignant tumor [ · Ribosome biogenesis (RiboSis) is a complex and crucial ... 标记为不相关
	What is it like to die? University of Minnesota's VR experience offers some answers. Star Tribune You take on the role of a 66-year-old man named Clay Crowder, coming to terms with the reality of a stage IV terminal lung cancer diagnosis. 标记为不相关
	AstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trials | Reuters Reuters The results come as AstraZeneca targets $80 billion in revenue by 2030, after first-quarter sales this week missed expectations on weaker oncology ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈